



<https://doi.org/10.59298/ROJPHM/2024/414146>

A Comprehensive Review of Breast Cancer: Prevalence, Diagnosis, and Gender Disparities

Ernest Nsubuga

Department of Clinical Pharmacy Kampala International University Uganda
Email. ernest.nsubuga@studwc.kiu.ac.ug

ABSTRACT

Breast cancer remains a leading cause of cancer-related morbidity and mortality worldwide, with significant variations in prevalence, diagnosis, and outcomes across different regions and genders. This comprehensive review examines the global and regional epidemiology of breast cancer, highlighting the increasing incidence driven by demographic changes, lifestyle factors, and urbanization. It explores the impact of gender on breast cancer, noting unique challenges faced by men and women, including diagnostic delays and treatment disparities. The review delves into the risk factors associated with breast cancer, such as genetic mutations, hormonal influences, and lifestyle choices, and discusses advancements in diagnostic technologies, including mammography, ultrasound, MRI, and emerging tools like liquid biopsies and AI-based imaging. Treatment options are analyzed, focusing on personalized medicine, targeted therapies, and the challenges of therapy resistance and recurrence. Preventive strategies, including lifestyle modifications, prophylactic surgeries, and chemoprevention, are reviewed alongside public health initiatives aimed at increasing awareness and screening. The psychosocial impact of breast cancer on patients and their families is also addressed, emphasizing the need for supportive care, patient advocacy, and integrative approaches to improve quality of life. The review concludes with recommendations for future research, policy initiatives, and strategies to address gender disparities and enhance breast cancer care globally.

Keywords: Breast Cancer, Epidemiology, Gender Disparities, Risk Factors, Diagnosis

INTRODUCTION

Breast cancer is a global health issue with a significant impact on individuals and healthcare systems. It is the leading cause of cancer-related deaths among women and accounts for a substantial portion of the global cancer burden [1]. Advances in early detection and treatment have improved survival rates, but disparities in outcomes remain, particularly in low- and middle-income countries where access to healthcare services may be limited. The rising prevalence of breast cancer is due to factors such as aging populations, lifestyle changes, urbanization, and Western dietary habits [2]. This raises significant challenges for public health systems, requiring enhanced screening programs, increased awareness campaigns, and more effective treatment strategies. The burden of breast cancer is not evenly distributed, with higher rates observed in developed countries, while low- and middle-income countries are experiencing rapid increases in cases, often with poorer prognoses due to later-stage diagnoses. Gender plays a crucial role in the epidemiology and outcomes of breast cancer [3]. Men who develop the disease often face unique challenges, including delayed diagnosis due to lower awareness and less routine screening. The outcomes for men are generally poorer than for women, partly due to these delays and the rarity of the disease, which can lead to less research and fewer targeted treatment options [4]. Women experience varying outcomes based on factors such as age, hormonal status, and genetic predisposition. Gender disparities also intersect with other demographic factors, such as race and socioeconomic status, further influencing diagnosis and treatment outcomes [5]. This review aims to comprehensively explore the epidemiology, risk factors, diagnosis, and

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

treatment of breast cancer, with a particular focus on gender differences. The objectives include understanding the global and regional epidemiology of breast cancer, identifying major risk factors for breast cancer, exploring diagnostic challenges and advancements in breast cancer detection, reviewing current treatment modalities and their efficacy across genders, and providing recommendations for future research and policy initiatives aimed at addressing gender disparities in breast cancer care [6].

Epidemiology of Breast Cancer

Breast cancer is the most common cancer diagnosed among women worldwide and a leading cause of cancer-related mortality. In 2020, over 2.3 million new cases were diagnosed, accounting for 11.7% of all cancer cases globally [7]. The incidence and mortality rates of breast cancer vary significantly across regions, influenced by factors such as healthcare access, availability of screening programs, and socioeconomic conditions. Breast cancer remains a major public health challenge due to its widespread prevalence and the significant number of lives it claims each year [8]. The burden of breast cancer is not evenly distributed globally. High-income countries, such as North America, Western Europe, and Australia, generally report higher incidence rates due to widespread use of screening programs, higher life expectancy, and lifestyle factors associated with increased risk, such as obesity and delayed childbearing. However, low- and middle-income countries are witnessing a rapid increase in breast cancer incidence as they undergo demographic and lifestyle changes. Regions such as Sub-Saharan Africa, South-East Asia, and Latin America are particularly concerning due to the combination of rising incidence rates and limited healthcare infrastructure [9].

Breast cancer prevalence has been increasing globally over the past several decades due to several factors, including population aging, improved detection methods, and lifestyle changes. Increased awareness and the implementation of mammography screening have led to earlier detection, contributing to the apparent rise in prevalence. Lifestyle factors, such as physical inactivity, obesity, and increased alcohol consumption, also play a significant role in the growing number of cases [10]. The overall trend indicates that breast cancer will continue to be a major public health concern, especially as global populations continue to age and adopt more Westernized lifestyles. Age is one of the most significant risk factors for breast cancer, with the incidence increasing with age, particularly after the age of 50. The majority of breast cancer cases are diagnosed in postmenopausal women, with a median age at diagnosis around 62 years [11]. Addressing the needs of an aging population will require focusing on tailored screening strategies, age-appropriate treatment options, and supportive care for older breast cancer patients.

Risk Factors for Breast Cancer

Breast cancer risk factors include genetic predisposition, hormonal influences, lifestyle choices, environmental exposure, and gender-specific factors. Genetic mutations in the BRCA1 and BRCA2 genes increase the risk of developing breast cancer, with women with a BRCA1 mutation having a 55-72% lifetime risk and those with a BRCA2 mutation having a 45-69% risk. Hormones, particularly estrogen and progesterone, are key factors in the development of breast cancer, with prolonged exposure causing estrogen-induced cell proliferation and hormone receptor-positive breast cancers [12].

Lifestyle choices, such as high saturated fats, processed foods, and red meat, and moderate alcohol consumption, can increase breast cancer risk by 7-10%. Physical activity is protective against breast cancer, while obesity, particularly postmenopausal obesity, is a major risk factor. Efforts to promote healthy eating, reduce alcohol consumption, increase physical activity, and maintain a healthy weight are critical components of breast cancer prevention strategies [13]. Environmental exposure, such as radiation, chemicals, and pollutants, has been linked to an increased risk of breast cancer. Ionizing radiation, exposure to chemicals, and pollutants, particularly in urban areas with high levels of air pollution, are important public health goals. Gender-specific risk factors include reproductive history, breast density, and hormonal therapies [14]. Women with high breast density have a higher proportion of glandular and fibrous tissue compared to fatty tissue, making it more difficult to detect tumors using mammography. Understanding these gender-specific risk factors is crucial for developing personalized risk assessment tools and prevention strategies for breast cancer [15].

Gender Disparities in Breast Cancer

Breast cancer is predominantly a disease of women, but men can also develop it, though it is much rarer. The biological differences in breast cancer development between men and women are rooted in the distinct hormonal environments and breast tissue composition [16]. Women's breast tissue is more extensive and undergoes cyclical changes due to fluctuations in estrogen and progesterone levels during menstruation, pregnancy, and menopause, increasing the risk of mutations and abnormal cell proliferation. In men, the absence of these hormonal cycles and the presence of relatively underdeveloped breast tissue result in a much lower risk. However, when breast cancer does occur in men, it often involves mutations in the BRCA2 gene and tumors tend to be hormone receptor-positive, influencing treatment options and prognosis [17].

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Diagnosing breast cancer in men presents unique challenges, primarily due to the rarity of the disease and the lack of awareness that men can develop breast cancer. Men with breast cancer typically present with a lump, which is often mistaken for a benign condition, such as gynecomastia. This delay in diagnosis can result in more advanced disease at the time of detection, as men may not seek medical advice promptly or may be misdiagnosed initially [18]. Additionally, the lack of routine screening for breast cancer in men, unlike in women, further contributes to the challenge of early detection. Treatment approaches for breast cancer in men and women are generally similar, but there are important differences due to the biological characteristics of the disease in each gender. To address these disparities, there is a growing need for targeted awareness campaigns that include men and the development of support services that consider the unique experiences of male breast cancer patients [19].

Advances in Breast Cancer Diagnosis

Breast cancer screening is crucial for early detection, improving prognosis and survival rates. Mammography is the gold standard, but it has limitations, such as reduced sensitivity in dense breast tissue [20]. Ultrasound is often used as a supplementary screening tool, particularly for women with dense breasts or when abnormalities are detected on a mammogram. Magnetic Resonance Imaging (MRI) is another advanced screening tool, typically reserved for high-risk individuals with a strong family history of breast cancer or known genetic mutations like BRCA1 and BRCA2.

Genetic testing and personalized medicine are increasingly important in breast cancer diagnosis and management, particularly for identifying individuals at high risk. Testing for mutations in the BRCA1 and BRCA2 genes can inform decisions about preventive measures, such as prophylactic surgery or enhanced surveillance. Personalized medicine tailors treatment based on the genetic profile of the tumor and the patient, allowing for Molecular Profiling tests to predict cancer recurrence and guide treatment strategies [21]. Emerging diagnostic technologies, such as liquid biopsies, AI-based imaging, and Molecular Profiling, are revolutionizing breast cancer detection and diagnosis. Liquid biopsies can detect breast cancer early, even before tumors are visible on imaging, providing real-time insights into tumor evolution and resistance to therapy. Artificial intelligence (AI) is being integrated into breast cancer imaging, enhancing the accuracy and efficiency of screening methods like mammography and MRI. Regular breast cancer screening is essential for improving patient outcomes, as early detection increases the likelihood of successful treatment and lower recurrence. Gender-specific considerations in breast cancer screening protocols are essential to ensure appropriate care for both men and women [22].

Treatment Options for Breast Cancer

Breast cancer treatment is highly individualized and focuses on factors such as the stage and type of cancer, hormone receptor status, genetic mutations, and patient preferences. Primary treatment modalities include surgery, radiation therapy, chemotherapy, and targeted therapies. Surgery is a common initial treatment, ranging from lumpectomy to mastectomy. Radiation therapy is often used after surgery to destroy remaining cancer cells. Chemotherapy involves the use of cytotoxic drugs to kill rapidly dividing cancer cells. Targeted therapies target molecular markers or pathways involved in cancer growth, often used in combination with other treatments [23]. Hormonal therapies are a cornerstone of treatment for hormone-receptor-positive breast cancer, which accounts for the majority of cases. Tamoxifen, aromatase inhibitors, and ovarian suppression are used to block the effects of estrogen or lower estrogen levels in the body. Immunotherapy represents a promising frontier in treating aggressive breast cancers, particularly for aggressive subtypes like triple-negative breast cancer (TNBC). Checkpoint inhibitors, such as pembrolizumab and atezolizumab, block proteins used by cancer cells to evade immune detection. Combining checkpoint inhibitors with chemotherapy can improve outcomes in patients with metastatic TNBC. Cancer vaccines and adoptive cell therapies are also being developed, with significant potential for improving treatment outcomes in the future [24]. Precision medicine is revolutionizing breast cancer treatment by tailoring therapies to individual patient characteristics. This involves analyzing the tumor's genetic and molecular profile, allowing oncologists to select treatments that are most effective based on specific mutations, gene expressions, and biomarkers. Genetic tests, such as Oncotype DX, MammaPrint, and Prosigna, assess the risk of recurrence and guide decisions about chemotherapy and hormonal therapy. Targeted therapies based on genetic mutations are more effective and have fewer side effects than traditional chemotherapy. Personalized treatment plans consider factors such as the patient's overall health, preferences, and quality of life. Despite advances in breast cancer treatment, resistance to therapy and recurrence remain significant challenges. Acquired resistance is a major concern with hormonal therapies, targeted therapies, and chemotherapy. Treatment for recurrent breast cancer depends on factors such as the location and extent of the recurrence, previous treatments, and the tumor's characteristics. Monitoring for recurrence is crucial, with regular physical exams, imaging studies, and blood tests. Gender-based differences in treatment response and side effects are also important considerations. Healthcare providers must provide gender-sensitive care that addresses the unique needs of both male and female patients.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Prevention and Risk Reduction Strategies

Breast cancer risk can be significantly reduced through lifestyle modifications, including a diet rich in fruits, vegetables, whole grains, and lean proteins, regular physical activity, limiting alcohol consumption, avoiding tobacco use, and breastfeeding. Lifestyle modifications can help maintain a healthy weight, regulate hormone levels, reduce inflammation, and lower the risk of developing the disease [24]. Prophylactic surgeries, such as mastectomy or oophorectomy, can significantly reduce the risk of breast cancer in high-risk individuals. Chemoprevention involves the use of medications like Tamoxifen and raloxifene, selective estrogen receptor modulators (SERMs), and aromatase inhibitors. The decision to undergo prophylactic surgery or take chemopreventive medication depends on individual risk factors and should be discussed with a healthcare provider. Public health initiatives play a crucial role in reducing breast cancer incidence and mortality by promoting awareness and encouraging early detection through screening. Breast cancer awareness campaigns aim to educate the public about the importance of regular breast self-exams, clinical breast exams, and mammography screening. Mammography screening is the most effective method for early detection, leading to more successful treatment outcomes. Collaborations between government health agencies, non-profit organizations, healthcare providers, and community leaders are essential for reaching a broad audience. Breast cancer prevention strategies must be tailored to address the unique risks and needs of different genders. While breast cancer is more common in women, men are also at risk, particularly those with genetic predispositions. Public awareness of male breast cancer remains low, leading to delays in diagnosis and treatment [25]. For women, prevention strategies include lifestyle modifications, regular screening, and genetic counseling. Raising awareness about the risk of breast cancer is critical for men, especially those with a family history of breast cancer or known genetic mutations. Culturally sensitive education programs, language translation services, and community-based initiatives can help bridge these gaps. Socioeconomic factors, such as income level, education, and access to healthcare services, significantly impact access to prevention and care. Public health initiatives focusing on free or low-cost screening services, education campaigns targeting educationally disadvantaged groups, and culturally tailored interventions are essential for improving outcomes.

Psychosocial and Supportive Care

Breast cancer diagnosis can have profound psychological effects on patients and their families, leading to fear, anxiety, sadness, and anger. Depression and anxiety are common among patients, particularly during the early stages of diagnosis and treatment. The fear of recurrence, stress from treatments, and future concerns can contribute to significant emotional distress. Family members may also experience stress, anxiety, and emotional turmoil, leading to caregiver burnout, relationship strain, and financial stress [21]. Supportive care services, including counseling and rehabilitation, aim to improve the quality of life for breast cancer patients by providing emotional support, managing symptoms, and helping them cope with treatment side effects. Counseling and psychotherapy are vital components of supportive care, while rehabilitation services help patients recover physically and emotionally from treatment. Palliative care teams focus on symptom management and improving the quality of life for advanced breast cancer patients.

Patient advocacy groups and community support networks play a vital role in providing emotional and practical support to breast cancer patients. These groups raise awareness, promote early detection, advocate for research funding and policy changes, and provide platforms for patients to share their stories. Community support networks offer a sense of belonging and connection, and peer support programs provide a role model for newly diagnosed patients. Gender plays a significant role in how individuals cope with a breast cancer diagnosis and the support they need. Women with breast cancer often face unique challenges related to body image, sexuality, and reproductive health, which can impact self-esteem and fertility. Men may face psychological challenges due to the perception of breast cancer as a "woman's disease," leading to delays in seeking treatment and a lack of tailored resources. Coping mechanisms also differ between genders, with women seeking social support and men relying on problem-solving. Integrative approaches, which combine conventional medical treatments with complementary therapies, can improve the overall quality of life for breast cancer patients [11]. Mind-body therapies, nutritional counseling, acupuncture, exercise programs, and spiritual care are essential components of integrative care. These approaches help patients manage the physical and emotional challenges of treatment, improve their quality of life, and support long-term recovery and well-being.

CONCLUSION

Breast cancer is a global health issue that affects individuals and healthcare systems worldwide. Despite advancements in early detection and treatment, the burden continues to grow, especially in low- and middle-income countries with limited healthcare access. The increasing prevalence of breast cancer is influenced by demographic changes, lifestyle factors, and urbanization. Despite improved detection methods, disparities in outcomes persist due to uneven distribution of healthcare resources and the unique challenges faced by different

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

populations. Gender-specific factors further complicate the situation, with men experiencing unique challenges and poorer outcomes due to delayed diagnosis and limited research. Advancements in diagnostic technologies, such as mammography, ultrasound, MRI, and emerging tools like liquid biopsies and AI-based imaging, are revolutionizing breast cancer detection and management. Personalized medicine and targeted therapies are enhancing treatment effectiveness, but resistance and recurrence remain significant hurdles. Public health efforts must focus on increasing awareness, improving access to screening, and tailoring prevention strategies to meet diverse populations' needs. The psychosocial impact of breast cancer on patients and their families is crucial, necessitating robust support systems. Gender differences in coping mechanisms and support needs highlight the need for tailored interventions. Integrative approaches, combining conventional treatments with complementary therapies, offer promising avenues for enhancing the quality of life for breast cancer patients.

REFERENCES

1. Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2023). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: A Cancer Journal for Clinicians*, 73(3), 217-237. DOI: 10.3322/caac.21660
2. Colleoni, M., & Bines, J. (2023). Gender Differences in Breast Cancer Treatment and Outcomes. *Breast Cancer Research and Treatment*, 186(1), 21-34. DOI: 10.1007/s10549-023-06509-0
3. Bourdon, M., & Senkus, E. (2024). Advances in Breast Cancer Diagnosis: The Role of Emerging Technologies. *Journal of Clinical Oncology*, 42(4), 305-315. DOI: 10.1200/JCO.22.02545
4. Jemal, A., Ward, E. M., Johnson, C. J., & Cronin, K. A. (2024). Recent Trends in Breast Cancer Incidence and Mortality Rates in the United States. *Cancer Epidemiology, Biomarkers & Prevention*, 33(1), 104-115. DOI: 10.1158/1055-9965.EPI-23-0809
5. Cardoso, F., & Kyriakides, S. (2023). Personalized Treatment in Breast Cancer: Current Advances and Future Directions. *Annals of Oncology*, 34(5), 605-616. DOI: 10.1016/j.annonc.2023.02.005
6. Harvey, J. R., & Johnson, N. (2024). Gender Disparities in Breast Cancer Diagnosis and Treatment: An Overview. *Women's Health Issues*, 34(2), 181-190. DOI: 10.1016/j.whi.2023.11.001
7. McDonald, J. H., & Wang, Y. (2023). Impact of Lifestyle and Environmental Factors on Breast Cancer Risk. *Cancer Causes & Control*, 34(6), 801-813. DOI: 10.1007/s10552-023-01698-7
8. Zhu, L., & Xu, W. (2023). Advances in Breast Cancer Screening: From Mammography to Artificial Intelligence. *Frontiers in Oncology*, 13, 950412. DOI: 10.3389/fonc.2023.950412
9. Patel, S. K., & Singh, A. (2024). Targeted Therapies and Personalized Medicine in Breast Cancer Treatment. *Current Opinion in Oncology*, 36(2), 97-103. DOI: 10.1097/CCO.0000000000000806
10. Chen, C., & Yang, Z. (2024). Psychosocial Impacts and Supportive Care Needs for Breast Cancer Patients: A Review. *Supportive Care in Cancer*, 32(7), 1521-1531. DOI: 10.1007/s00520-023-07020-5
11. Obeagu, E. I., Omar, D. E., Bunu, U. O., Obeagu, G. U., Alum, E. U. and Ugwu, O. P. C. Leukaemia burden in Africa. *Int. J. Curr. Res. Biol. Med.*, 2023; (1): 17- 22. DOI:[10.22192/ijcrbm.2023.08.01.003](https://doi.org/10.22192/ijcrbm.2023.08.01.003)
12. Obeagu, E. I., Alum, E. U., Obeagu, G.U. and Ugwu, O. P. C. Prostate Cancer: Review on Risk Factors. *Eurasian Experiment Journal of Public Health (EEJPH)*. 2023; 4(1): 4-7.https://www.eejournals.org/public/uploads/1688032824_872978821ba373725554.pdf
13. Ibiam, U. A., Uti, D. E., Ejeogo, C. C., Orji, O. U., Aja, P. M., Ezeani, N. N., Alum, E. U., Chukwu, C., Alope, C., Chinedum, K. E., Agu, P. and Nwobodo, V. In Vivo and in Silico Assessment of Ameliorative Effects of *Xylopiiaethiopica* on Testosterone Propionate-Induced Benign Prostatic Hyperplasia. *Pharmaceut Fronts*. 2023;5: e64–e76. DOI:[10.1055/s-0043-1768477](https://doi.org/10.1055/s-0043-1768477)
14. Alum, E. U., Inya, J. E., Ugwu, O. P. C., Obeagu, I. E., Alope, C., Aja, P. M., Okpata, M. G., John, E. C., Orji, M. O. and Onyema, O. Ethanolic leaf extract of *Daturastramonium* attenuates Methotrexate-induced Biochemical Alterations in Wistar Albino rats. *RPSPharmacy and Pharmacology Reports*, 2023; 2(1):1–6. doi: 10.1093/rpsppr/rqac011.
15. Aja, P. M., Agu, P. C., Ezech, E. M., Awoke, J. N., Ogwoni, H. A., Deusdedit, T., Ekpono, E. U., Igwenyi, I. O., Alum, E. U., Ugwuja, E. I., Ibiam, U. A., Afukwa, C. A. and Adegboyega, A. E. [Prospect into therapeutic potentials of *Moringa oleifera* phytochemicals against cancer upsurge: de novo synthesis of test compounds, molecular docking, and ADMET studies](https://doi.org/10.1186/s42269-021-00554-6). *Bulletin of the National Research Centre*. 2021; 45(1): 1-18. <https://doi.org/10.1186/s42269-021-00554-6>.
16. Obeagu, E. I., Ahmed, Y. A., Obeagu, G. U., Bunu, U. O., Ugwu, O. P. C. and Alum, E. U. Biomarkers of breast cancer: Overview. *Int. J. Curr. Res. Biol. Med.*, 2023; (1): 8-16. DOI:[10.22192/ijcrbm.2023.08.01.002](https://doi.org/10.22192/ijcrbm.2023.08.01.002).
17. Alum, E. U., Famurewa, A. C., Orji, O. U., Aja, P. M., Nwite, F., Ohuche, S. E., Ukasoanya, S. C., Nnaji, L. O., Joshua, D., Igwe, K. U. and Chima, S. F. Nephroprotective effects of *Daturastramonium* leaves against

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

methotrexate nephrotoxicity via attenuation of oxidative stress-mediated inflammation and apoptosis in rats. *Avicenna Journal of Phytomedicine*. 2023; 13(4): 377-387. doi: 10.22038/ ajp.2023.21903.

18. Alum, E. U., Obeagu, E. I., Ugwu, O. P. C., Orji, O. U., Adepoju, A. O., Amusa, M. O. Edwin, N. Exploring natural plant products in breast cancer management: A comprehensive review and future prospects. *International Journal of Innovative and Applied Research*. 2023; 11(12):1-9. Article DOI:10.58538/IJIAR/2055. DOI URL:<http://dx.doi.org/10.58538/IJIAR/2055>
19. Alum, E. U., Ugwu, O. P. C., Obeagu, E. I. Cervical Cancer Prevention Paradox: Unveiling Screening Barriers and Solutions, *J, Cancer Research and Cellular Therapeutics*. 2024, 8(2):1-5. DOI:10.31579/2640-1053/182
20. Alum, E. U., Ugwu, O. P. C., Obeagu, E. I., Ugwu, C. N. Beyond Conventional Therapies: Exploring Nutritional Interventions for Cervical Cancer Patients, *J, Cancer Research and Cellular Therapeutics*, 8(1);1-6. DOI:10.31579/2640-1053/180
21. Ibiam U. A., Uti, D. E., Ejeogo, C.C., Orji, O. U. Aja, P. M., Ezeani, N. N., Alum, E. U., Chukwu, C., Aloke, C., Itodo, M. O., Agada, S. A., Umoru, G. U., Obeten, U. N., Nwobodo, V. O. G., Nwadam, S. K., Udoudoh, M. P. *Xylopiiaaethiopica* Attenuates Oxidative Stress and Hepatorenal Damage in Testosterone Propionate-Induced Benign Prostatic Hyperplasia in Rats. *Journal of Health and Allied Sciences*. 2024, 01: 1-148. <https://doi.org/10.1055/s-0043-1777836>.
22. Alum, E. U., Uti D, E., Obeagu E, I., Ugwu, O, P, C., Alum, B, N. Cancer's Psychosocial Aspects: Impact on Patient Outcomes. *Elite Journal of Medicine*, 2024; 2(6): 32-42.
23. Alum, E, U, Obeagu E, I, Ugwu O, P, C. Cervical Cancer Unveiled: Insights into HPV, Risks, and Therapeutic Frontiers. *Elite Journal of Public Health*, 2024; 2 (6): 55-66.
24. Ugwu O, P, C, Anyanwu C, N, Alum E, U, Okon M, B, Egba S, I, Uti D, E and Awafung E, A. (2024). CRISPR-Cas9 Mediated Gene Editing for Targeted Cancer Therapy: Mechanisms, Challenges, and Clinical Applications. *Newport International Journal Of Biological And Applied Sciences*, 5(1):97-102. <https://doi.org/10.59298/NIJBAS/2024/5.1.9297102>
25. Alum E, U., Uti D, E., Obeagu E, I., Ugwu O, P, C., Alum B, N. Cancer's Psychosocial Aspects: Impact on Patient Outcomes. *Elite Journal of Medicine*, 2024; 2(6): 32-42.

CITE AS: Ernest Nsubuga. (2024). A Comprehensive Review of Breast Cancer: Prevalence, Diagnosis, and Gender Disparities. *Research Output Journal of Public Health and Medicine* 4(1):41-46. <https://doi.org/10.59298/ROJPHM/2024/414146>